FDA grants marketing approval to GSK’s diabetes drug based on Novozymes’ Veltis technology
The new drug uses Novozymes’ Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week. The approval follows
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.